Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective.

Creator(s)

Chance S. Friesen, Children's Mercy HospitalFollow
Sherwin S. Chan, Children's Mercy HospitalFollow
Jonathan B. Wagner, Children's Mercy HospitalFollow
Chelsea Hosey-Cojocari, Children's Mercy HospitalFollow
Iván L Csanaky, Children's Mercy HospitalFollow
Valentina Shakhnovich, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

5-2021

Identifier

DOI: 10.1111/cts.12952; PMCID: PMC8212707

Abstract

Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.

Journal Title

Clin Transl Sci

Volume

14

Issue

3

First Page

781

Last Page

783

Comments

Grant support

• K23 DK115827/DK/NIDDK NIH HHS/United States
• UL1 TR002366/TR/NCATS NIH HHS/United States
• UL1TR002366/University of Kansas Clinical and Translational Science Institute
• 5K23DK115827-01/University of Kansas Clinical and Translational Science Institute

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Publisher's Link: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12952

Recommended Citation

Friesen CS, Chan SS, Wagner JB, Hosey-Cojocari C, Csanaky IL, Shakhnovich V. Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective. Clin Transl Sci. 2021;14(3):781-783. doi:10.1111/cts.12952